Despite significant improvements in the primary success rate of the medical and surgical treatments for atherosclerotic disease, including angioplasty, bypass grafting, and endarterectomy, secondary failure due to late restenosis continues to occur in 30-50% of individuals. Restenosis and the later stages in atherosclerotic lesions are due to a complex series of fibroproliferative responses to vascular injury involving potent growth-regulatory molecules (such as platelet-derived growth factor and basic fibroblast growth factor) and resulting in vascular smooth muscle cell (VSMC) proliferation, migration, and neointimal accumulation. We show here, based on experiments with both taxol and deuterium oxide, that microtubules are necessary for VSMCs to undergo the multiple transformations contributing to the development of the neointimal fibroproliferative lesion. Taxol was found to interfere both with platelet-derived growth factor-stimulated VSMC migration and with VSMC migration and with VSMC proliferation, at nanomolar levels in vitro. In vivo, taxol prevented medial VSMC proliferation and the neointimal VSMC accumulation in the rat carotid artery after balloon dilatation and endothelial denudation injury. This effect occurred at plasma levels approximately two orders of magnitude lower than that used clinically to treat human malignancy (peak levels achieved in this model were -50-60 nM). Taxol may therefore be of therapeutic value in preventing human restenosis with minimal toxicity. (J. Clin. Invest. 1995Invest. . 95:1869Invest. -1876
Introduction
Microtubules, ubiquitous cellular constituents present in all eukaryotic cells, are required for normal cellular activities. They are an essential component of the mitotic spindle needed for cell division and are required for maintaining cell shape and a variety of other cellular activities, such as motility, anchorage, transport between cellular organelles, extracellular secretory processes (1) , modulation of the interactions of growth factors with cell surface receptors, and intracellular signal transduction (2) (3) (4) (5) . Furthermore, microtubules probably play a critical regulatory role in cell replication, as both the c-mos oncogene and CDC-2-kinase, which regulate entry into mitosis, bind to and phosphorylate tubulin (6, 7) and the product of both the tumor suppressor gene p53 and the T-antigen of simian virus 40 bind tubulin in a ternary complex (8) . Microtubules are in dynamic equilibrium with their soluble protein subunits, the a-and f3-tubulin heterodimers (1) . Assembly under physiologic conditions requires GTP and certain microtubule-associated and -organizing proteins as cofactors; on the other hand, high calcium and cold temperature cause depolymerization.
Interference with this normal equilibrium between the microtubule and its subunits would therefore be expected to disrupt cell division and motility, as well as other activities dependent on microtubules. This strategy has been used with significant success in the treatment of certain malignancies. Indeed, antimicrotubule agents are among the most important anticancer drugs currently used. The vinca alkaloids, which promote microtubule disassembly, play principal roles in the chemotherapy of most curable neoplasms, including acute lymphocytic leukemia, Hodgkin's and non-Hodgkin's lymphomas, and germ cell tumors, as well as in the palliative treatment of many other cancers.
The newest and most promising antimicrotubule agent under research is taxol. Taxol, the prototype of the taxane class of compounds, is a highly derivatized diterpenoid (9) isolated from the bark from the Pacific yew, Taxus brevifolia. Taxol induces tubulin polymerization, resulting in the formation of abnormally stable and nonfunctional microtubules (10, 11) . This is a novel mechanism compared with classic antimicrotubule agents such as colchicine and the vinca alkaloids, which induce microtubule disassembly. Taxol has one of the broadest spectra of antineoplastic activity, renewing serious interest in chemotherapeutic strategies directed against, microtubules (for review, see reference 12) . In recent phase II studies, taxol has shown significant activity in advanced and refractory ovarian cancer (13, 14) and malignant melanoma (15) , as well as in cancers of the breast (16) , head and neck, and lung.
Despite significant improvements in the primary success rate of the medical and surgical treatments for atherosclerotic disease, including angioplasty, bypass grafting, and endarterectorny, secondary failure due to late restenosis continues to occur in 30-50% of individuals. During angioplasty, intraarterial balloon catheter inflation results in deendothelialization, disruption of the internal elastic lamina, and probably injury to some medial smooth muscle cells. Although restenosis after such vascular injury likely results from the interdependent actions of the ensuing thrombosis, inflammation, elaboration of potent growth-regulatory molecules (such as PDGF basic fibroblast growth factor), and smooth muscle cell accumulation (17) , the final common pathway evolves as a result of vascular smooth muscle cell (VSMC)' dedifferentiation from a contractile to a secretory phenotype (18) . This involves, principally, VSMC secretion of matrix metalloproteinases, which degrade the surrounding basement membrane (19) , proliferation, chemotactic migration into the intima (20-27), and secretion of a large extracellular matrix, forming the neointimal fibroproliferative lesion.
Since the pattern of the VSMC phenotypic dedifferentiation after arterial injury mimics that of neoplastic cells (i.e., abnormal proliferation, growth-regulatory molecule and protease secretion, migration, and basement membrane invasion), we tested the hypothesis that interference with VSMC microtubule function by taxol would inhibit restenosis by preventing neointimal VSMC accumulation. Taxol was found to stabilize microtubule polymerization and to interfere with PDGF-stimulated intracellular signaling, proliferation, and migration, at nanomolar levels in vitro. In vivo, taxol prevented neointimal smooth muscle cell accumulation in the rat carotid artery after balloon dilatation and endothelial denudation injury at plasma levels one to three orders of magnitude lower than peak plasma levels achieved with standard doses and schedules used clinically to treat human malignancy and at pharmacologic exposures substantially lower than those associated with cytotoxic effects in the clinic. Thus, microtubule stabilization offers a potentially viable approach to preventing neointimal VSMC accumulation after injury by interfering with a diverse array of sensitive intracellular processes that are likely to have an important role in the development of restenosis. Although the biology of human restenosis may differ somewhat from that of animal models, particularly in the kinetics of cell proliferation (28, 29) , the ability of taxol to alter a variety of cellular activities (including intracellular signaling, VSMC proliferation and migration, and potentially matrix production) increases the likelihood of success in preventing human restenosis with minimal toxicity over other strategies based solely on the inhibition of cellular proliferation.
Methods
Cell culture and immunocytochemistry. Rat VSMCs were isolated and cultured according to techniques previously described (30 4 h at 370C in a humidified 5% CO2 atmosphere. Insignificant cellular proliferation occurs (i.e., VSMC number remains essentially constant) during the 4-h time course of these assays. At the conclusion of the experiment, the filters were removed and the cells were fixed and stained with hematoxylin and eosin. After the cells on the upper surface of the filter (noninvaders) were mechanically removed, the cells on the underside (invaders) were counted under X400 (four random fields were counted per filter, all experiments were run in triplicate, and each triplicate assay was repeated three times on separate occasions using different VSMC preparations). Chemotaxis was assayed in analogous fashion in the Boyden chambers previously described, except that the reconstituted basement membrane was omitted. We have previously shown that these Boyden assays specifically measure VSMC chemotaxis to a PDGF gradient (rather than chemokinesis), since no significant migration occurs when equal concentrations of PDGF are placed on both sides of the filter barrier or when PDGF is replaced by a nonspecific agent such as BSA (19) .
Metalloproteinase activity. Gelatinase zymography was performed on the supernatants removed after the 4-h conclusion of the Boyden assays. Gelatin-degrading metalloproteinases (including the 72-kD type IV collagenase) secreted into the media by VSMCs were detected with SDS-PAGE using gels containing 0.1% gelatin. Gelatinase activity was then reconstituted in 2.5% Triton X-100 for 30 min at 230C, followed by 0.2 M NaCl, 5 Carotid artery injury model. 6-mo-old Wistar rats were anesthetized with 20 mg/kg body weight pentobarbital, 2 mg/kg body weight ketamine, and 4 mg/kg body weight xylazine intraperitoneally under a protocol approved by the National Institute on Aging Animal Care Committee. The left external carotid artery was cannulated with a 2-French Fogarty embolectomy catheter, which was then inflated with saline and passed three times up and down the common carotid artery to produce a distending, deendothelializing injury. The animals were treated with 2 mg/kg body weight taxol in vehicle; control animals were treated with vehicle alone (13.4 ml/kg body weight per d of 1:2:2:165 DMSO/Cremephor EL (Sigma Chemical Co.)/ethanol/PBS) 2 h after the injury. Taxol or vehicle alone was administered daily for the next 4 d. In other experiments (not involving taxol), rats were equilibrated with 25% 2H20 drinking water for 6 wk before carotid injury (a duration estimated to result in > 23% 2H20 replacement of body water) and until the carotid arteries were removed for study. After 11 d, the animals were anesthetized as previously described, and the carotid artery was isolated, fixed in 10% buffered formalin, and embedded in paraffin. Cross sections of the carotids were mounted on microscope slides and stained with hematoxylin and eosin. Morphometric analysis was performed from three to four individual sections from the middle of each injured arterial segment. The image of each carotid artery section was projected onto a digitizing board (SigmaScan, Jandel Scientific, Corte Madera, CA), and the cross-sectional areas of the intima and the media were measured. Experiments were coded so that surgery and data analysis were performed without knowledge of treatment group.
Measurement of in situ VSMC proliferation. In some animals undergoing the carotid artery injury protocol, the effect of taxol versus vehicle on in situ VSMC proliferation was measured via BrdU incorporation at day 2 after injury (approximately the point of maximal VSMC ptoliferation rate after carotid artery balloon injury) (33) . Briefly, taxol-and vehicle-treated rats were injected subcutaneously with three doses of BrdU (30 mg/kg) at 30, 38, and at 46 h after injury. The carotid artery sections were harvested at 48 h after injury, and histologic sections were incubated with mouse anti-BrdU mAbs (Boehringer Mannheim) to label BrdU incorporation. Proliferating VSMCs were identified by positive staining with the anti-BrdU antibody. The fraction of BrdU-positive medial VSMC nuclei per cross section (no neointima present at day 2) was compared between taxol and vehicle treatment groups.
Measurement of plasma taxol. Plasma was obtained from pairs of rats at 0.5, 1, 2, 3, 4, 6, and 24 h after treatment with taxol (2 mg/kg i.p.) and from two vehicle-treated animals serving as controls and was stored at -20°C. Plasma taxol concentrations were measured at The Johns Hopkins Oncology Center (Baltimore, MD) by HPLC using a modification of the method described by Longnecker et al. (34) . Briefly, 15 kl of 0.1 mmol/liter internal standard (n-cyclohexylbenzamide) was added to a 1-ml plasma sample. Taxol and internal standard were extracted with 5 ml of ethyl acetate, and the organic layer was dried under a nitrogen stream. The residue was reconstituted with 200 Al of acetonitrile. 25 A1 of the solution was injected onto the column using an autosampler. A C.8 column, 150 x 4.6 mm, 5 am (Jones Chromatography, Lakewood, CO), with a C18 Guard-Pak precolumn insert (Waters Chromatography, Marlborough, MA) was used. The separation was achieved at a flow rate of 1.5 ml/min beginning with 65% Milli-Q water (Waters Chromatography)/35% acetonitrile for 6 min, followed by a linear gradient to 35% Milli-Q water/65% acetonitrile over 17 min. Ultraviolet detection was performed at 227 nm. The retention times for the internal standard and taxol were 9 and 17.4 min, respectively. The limit of taxol quantification was 0.02 kmol/liter, the within-run analytic coefficient of variation was 3%, and the total (between-day) analytic coefficient of variation was 8.5%. Chromatographic data were acquired by and subsequently analyzed using an automated chromatographic data system (PF Nelson 2600; Perkin-Elmer Corp., Cupertino, CA).
Results and Discussion
Effect oftaxol on microtubule polymerization. In in vitro experiments, nanomolar concentrations of taxol (18-h exposure at 37TC) caused a dose-dependent increase in microtubule polymerization in VSMCs cultured on plastic (Fig. 1) , cells that also exhibit the dedifferentiated phenotype (30) . These results are striking in comparison with the "clinically relevant" micromolar (0.1-10) levels of taxol ordinarily required to cause microtubule bundling in various cultured cancer cell models (35-37). Interestingly, in phase I clinical trials for leukemia, the magnitude of the patient's clinical response to taxol was related to the in vitro sensitivity of leukemic blasts to form microtubule bundles (38, 39 (Fig. 3) .
Effects of taxol on proliferation. In addition to cell recruitment and migration, the various growth-regulatory molecules elaborated after arterial injury, such as PDGF and basic fibroblast growth factor, are also implicated in mitogenesis and cellular proliferation (46) (47) (48) (49) (50) (51) (52) (53) (54) In the rat, taxol at 2 mg/kg i.p., which resulted in peak plasma levels of 50-60 nM and trace levels (below the 20 nM HPLC quantitation limit) at 24 h, also inhibited in vivo medial VSMC proliferation (assessed by in situ BrdU labeling) by approximately half versus vehicle alone (11±3% versus 20±6%, respectively, mean±SD [n = 3 per group], P < 0.05) at day 2 after carotid balloon injury. These levels of inhibition are comparable to those achieved in in vitro conditions. These data are consistent with considerable experimental evidence that normal functional integrity of the microtubules is critical in the transmission of proliferative transmembrane signals from cell surface receptors to the nucleus (2-5, 58-61).
Effects of microtubule stabilization on neointimal formation. Thus, taxol significantly inhibits cultured VSMC in vitro invasion and proliferation through interference with microtubule function, disrupting locomotion and the facility to alter shape as well as growth factor-stimulated cell proliferation, at concentrations 10-to 1,000-fold lower than peak plasma concentrations achieved in treating human cancers (depending on the duration of the infusion schedule [3-24 hD) (62) and at pharmacological exposures substantially lower than those associated with minimal cytotoxicity in oncologic therapeutics (63, 64) . This microtubule mechanism is supported by the analogous results of 2H20 experiments, which exert comparable microtubule effects via different underlying mechanisms. Furthermore, taxol, at doses achieving peak plasma levels approxi- Deuterium Oxide % (vlv) Figure 3 . 2H20 dose-dependent inhibition of DNA syn- mately two orders of magnitude lower than those achieved in humans at doses used clinically to treat human malignancy, significantly inhibited VSMC proliferation measured near the time of its peak occurrence after vascular injury. To determine whether microtubule stabilization/hyperpolymerization could affect in vivo neointimal formation, we administered taxol in a rat model of arterial injury. Taxol administration in vivo (2 mg/ kg i.p. for 5 d beginning 2 h after injury) inhibits the accumulation of neointimal smooth muscle cells in a rat carotid artery balloon catheter injury model, assessed at day 11, compared with vehicle alone (Fig. 4) . Quantitative analysis of injured carotid segments showed that taxol treatment reduced the neointimal area by 70% compared with vehicle-treated animals (P < 0.0002) ( Table I) . Several of the taxol-treated animals showed virtually no discernable neointima (in the presence of denuded endothelium, proving injury), whereas all vehicletreated animals demonstrated neointimal thickening. In separate experiments with this carotid injury model, experiments performed in rats -95% equilibrated with 25% 2H20 demonstrate a -40% reduction in neointimal area compared with normal H20-equilibrated control animals (P < 0.05) ( Fig. 5 ; Table  II ), a degree of inhibition comparable to that observed at the same 2H20 level in the Boyden chamber assay.
Although taxol and 2H20 potentially affect multiple intracellular processes, the coincidence of their parallel effects on microtubules and on VSMC functionality at multiple levels suggests that microtubule stabilization is the likely mechanism of action, though alternative, unforeseen mechanisms may be responsible for these observed functional changes. Moreover, antimicrotubule agents and particularly those that stabilize and enhance microtubule polymerization, such as taxol, constitute some of the most potent antineoplastic strategies known, probably because of interference with a diverse array of vital cellular functions more critical to the transformed cell compared with the quiescent, differentiated cell. These experiments with taxol and 2H20 implicate microtubules in the control of the VSMC intracellular mechanisms necessary for promoting the multiple transformations involved in the fibroproliferative lesion after arterial injury, making them particularly strategic targets to influence the outcome.
Based on the in vitro sensitivity of cultured human VSMCs to form taxol-induced microtubule polymerization, it may be possible to predict human clinical responses to these agents after arterial injury, as is true for certain leukemias (38, 39) . Although the in vivo systemic taxol dose used in these experiments (yielding peak levels of 50-60 nM and trough plasma levels substantially lower than 20 nM) is significantly lower than that ordinarily achieved with doses and schedules commonly used to treat human cancers (approximately two orders of magnitude lower), even lower systemic dosing with sustained or even improved efficacy could be possible by combining a pretreatment regimen with the optimal treatment duration. Ultimately, local sustained-release delivery systems may offer the best solution to prevent human restenosis after angioplasty, enabling delivery of high local concentrations of drug and essentially eliminating problems of systemic toxicity. The development of taxol-impregnated biopolymer-coated stenting may offer a realistic approach to address these issues. These results offer the possibility of a chemotherapeutic approach to prevent clinical restenosis after angioplasty and other vascular surgical procedures, including bypass surgery, and possibly to attenuate cardiac transplantation-associated atherosclerosis.
